Meeting abstracts comparing metabolic surgery with incretin drugs report larger one-year weight change and higher remission rates, plus better long-term heart and kidney signals in older adults.
What happened
At the 2026 ASMBS annual meeting in San Antonio, investigators presented a systematic review of 30 head-to-head clinical studies covering more than 430,000 people. Teams from Yale, Coreva-Scientific, Vanderbilt, and UT Health San Antonio reported that after one year, surgery patients lost more than 20% more weight than the GLP-1 group. That is a relative gap, not a 20-point difference in body-weight percentage. Remission gaps favored surgery for type 2 diabetes (about +42 percentage points), high blood pressure (about +12.8), and high cholesterol (about +20.8).
A second ASMBS release on the same meeting day looked at adults 65 and older with obesity and diabetes in Epic Cosmos records. After matching, the surgery group had fewer major heart events over five years (11.5% versus 13.6%), less severe kidney disease (9.1% versus 12.4%), and less diabetic eye disease (5.8% versus 9.0%). First-year average weight change was 17.3% after surgery versus 4.2% on the drugs, while A1c improvement looked similar.
Authors and ASMBS commenters stressed that these are real-world and review data, not a new randomized trial that ranks every patient path.
What it means
For readers comparing paths, the meeting package is strongest as context: operations still show larger average weight and comorbidity shifts than medication alone in the populations studied. It also supports asking surgical and medical teams how durability, side effects, cost, and restart risk after stopping a drug fit a specific case.
Older adults were not excluded from the heart-outcome analysis. That is a signal for shared decision-making, not a blanket age rule.
What it does not mean
It is not proof that every person should choose surgery, or that GLP-1 medicines have no role. It is not individualized advice, not a cost quote, and not a claim that combination care was tested here. Meeting abstracts are not the same as a finished peer-reviewed paper with full methods.
Sources
- ASMBS primary release, May 6, 2026 weight and remission comparison
- ASMBS primary release, May 6, 2026 older-adult heart outcomes
Related guide
Bariatric surgery Information Center hub
Related discussion
Educational information only. Not medical advice. Do not start, stop, or change treatment from this brief.